Each year, Capgemini publishes an in-depth analysis of a major life sciences issue. In their 9th edition of Vision & Reality, entitled “Patient Adherence: The Next Frontier in Patient Care," they focus on patient adherence – or rather the lack thereof. There is growing recognition that non-adherence to prescribed treatment is a major public health issue. In the US, it is estimated that additional care for non-adherent patients results in more than $300 billion of unnecessary costs to the healthcare industry each year.
For pharmaceutical companies, improvement in patient adherence represents a significant revenue opportunity that is largely untapped today. In this report, they analyze the current state of patient adherence and the challenges and key success factors involved in improving it.
To read the full report please click here.
